Evidence-Based Medicine Guidelines
Dexamethasone plus HT3 receptor antagonists or metoclopramide vs dexamethasone alone for chemotherapy-induced vomiting
Dexamethasone plus HT3 receptor antagonists or metoclopramide vs dexamethasone alone for chemotherapy-induced vomiting is a topic covered in the Evidence-Based Medicine Guidelines.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Dexamethasone Plus HT3 Receptor Antagonists or Metoclopramide Vs Dexamethasone Alone for Chemotherapy-induced Vomiting." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/451089/all/Dexamethasone_plus_HT3_receptor_antagonists_or_metoclopramide_vs_dexamethasone_alone_for_chemotherapy_induced_vomiting.
Dexamethasone plus HT3 receptor antagonists or metoclopramide vs dexamethasone alone for chemotherapy-induced vomiting. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/451089/all/Dexamethasone_plus_HT3_receptor_antagonists_or_metoclopramide_vs_dexamethasone_alone_for_chemotherapy_induced_vomiting. Accessed March 27, 2023.
Dexamethasone plus HT3 receptor antagonists or metoclopramide vs dexamethasone alone for chemotherapy-induced vomiting. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/451089/all/Dexamethasone_plus_HT3_receptor_antagonists_or_metoclopramide_vs_dexamethasone_alone_for_chemotherapy_induced_vomiting
Dexamethasone Plus HT3 Receptor Antagonists or Metoclopramide Vs Dexamethasone Alone for Chemotherapy-induced Vomiting [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2023 March 27]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/451089/all/Dexamethasone_plus_HT3_receptor_antagonists_or_metoclopramide_vs_dexamethasone_alone_for_chemotherapy_induced_vomiting.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Dexamethasone plus HT3 receptor antagonists or metoclopramide vs dexamethasone alone for chemotherapy-induced vomiting
ID - 451089
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/451089/all/Dexamethasone_plus_HT3_receptor_antagonists_or_metoclopramide_vs_dexamethasone_alone_for_chemotherapy_induced_vomiting
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
